Method for determining blood concentration of colistin E and detection product
The blood concentration determination method of polymyxin E by liquid chromatography-mass spectrometry has solved the shortcomings in comprehensiveness and accuracy of the existing TDM methods, and achieved accurate detection of polymyxin E, which is suitable for clinical practice. The testing requirement of using colistin sulfate or CMS improves treatment effectiveness and patient safety.
Patent Information
- Application Number
- CN202411342194.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-12-06
AI Technical Summary
The existing TDM methods of polymyxin-based drugs have shortcomings in terms of comprehensiveness, accuracy and accessibility, resulting in inaccurate assessment of drug efficacy, affecting treatment effect and patient safety, especially in resource-limited environments. accomplish.
The blood concentration concentration of polymyxin E is determined based on the liquid chromatography-mass spectrometry method. The blood concentration of polymyxin E is calculated by classification of molecular weight and deducting sulfuric acid content, providing a more comprehensive and accurate analysis. As a result, it is suitable for polymyxin E detection when using colistin sulfate or CMS in clinical use.
It improves the accuracy and simplicity of operation of polymyxin E detection, can more comprehensively reflect the clinical pharmacodynamic activity of the drug, and is suitable for environments with limited resources to ensure treatment effect and patient safety.
Smart Images

Figure CN119086772A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of colistin detection, and in particular to a method for determining colistin blood concentration and a detection product. Background Art
[0002] In today's medical field, the problem of antibiotic resistance is becoming increasingly serious, especially for infections caused by carbapenem-resistant Gram-negative bacteria (CRO), such as Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (KP). The emergence and prevalence of these resistant strains pose a huge challenge to public health. In this context, polymyxins have become the first-line choice for clinical treatment again because of their efficacy against almost all CROs, and are regarded as the last line of defense for the treatment of multidrug-resistant Gram-negative infections.
[0003] Existing polymyxins, including colistin E, are usually monitored for therapeutic drug monitoring (TDM) using high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). These methods can provide important information about drug concentrations to the clinic, helping doctors optimize treatment plans to achieve therapeutic effects and reduce adverse reactions. However, the therapeutic window of polymyxins is narrow, and the effective therapeutic concentration is very close to the concentration range that causes nephrotoxicity, which requires accurate drug concentration monitoring during treatment.
[0004] Although existing TDM methods have met clinical needs to a certain extent, they have some significant limitations. First, polymyxins are complex mixtures produced by biofermentation, with more than 30 components, of which polymyxin E1 and polymyxin E2 are the main active ingredients. Existing TDM methods mainly focus on these two main components during concentration calculation, while ignoring other isomers with smaller contents but equally active. This selective monitoring leads to an incomplete evaluation of the overall clinical pharmacodynamic activity of the drug, which may not accurately reflect the actual therapeutic effect of the drug.
[0005] In addition, existing TDM methods have certain complexities and technical requirements in actual operation, which limits their application in resource-limited settings. For example, high-performance liquid chromatography and liquid chromatography-mass spectrometry require expensive equipment and professional technicians, which are difficult to implement in some primary care institutions. Therefore, the popularity and accessibility of these methods are limited.
[0006] In summary, although the existing TDM methods for polymyxins are helpful in guiding clinical treatment to a certain extent, they are insufficient in terms of comprehensiveness, accuracy, and accessibility. These limitations may lead to inaccurate evaluation of drug efficacy, affecting treatment efficacy and patient safety. Therefore, it is necessary to develop new TDM methods to monitor the concentration of polymyxins in a more comprehensive, accurate, and convenient way, so as to better guide clinical treatment, improve treatment efficacy, reduce adverse reactions, and ensure patient safety.
[0007] In view of this, the present invention is proposed. Summary of the invention
[0008] The first object of the present invention is to provide a method for determining the blood concentration of colistin E and a detection product. The method for determining the blood concentration of colistin E has the advantages of simple operation, strong versatility, and is suitable for conducting therapeutic drug monitoring of polymyxin E when colistin sulfate or CMS is used clinically.
[0009] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:
[0010] In a first aspect, the present invention provides a method for determining the blood concentration of polymyxin E. The method for determining the blood concentration of polymyxin E is based on liquid chromatography-mass spectrometry, which classifies polymyxin E by molecular weight and deducts the sulfuric acid content therefrom to obtain the blood concentration of polymyxin E.
[0011] In an optional embodiment, the method for determining the blood concentration of polymyxin E comprises:
[0012] Prepare a colistin sulfate standard, and calculate the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 by deducting the sulfuric acid content from the molecular weight; and prepare a target sample to be tested corresponding to the whole blood sample to which an internal standard is added;
[0013] Based on liquid chromatography-mass spectrometry, the colistin sulfate standard and the target sample are tested to obtain the detection data of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard, and the target sample;
[0014] constructing standard curves of the first active ingredient mixture and the second active ingredient mixture respectively according to the detection data;
[0015] According to the standard curve, the measured concentrations of the first active ingredient mixture and the second active ingredient mixture in the target sample to be tested are calculated; and the blood concentration of polymyxin E in the target sample to be tested is calculated according to the measured concentrations of the first active ingredient mixture and the second active ingredient mixture.
[0016] In an optional embodiment, the colistin sulfate standard is prepared, and the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 are calculated by molecular weight, minus the sulfuric acid content, respectively, including:
[0017] The average molecular weight of polymyxin E was calculated based on the first active ingredient mixture with a molecular weight of 1168 and the second active ingredient mixture with a molecular weight of 1154;
[0018] Calculating the percentage of active ingredients in the first active ingredient mixture and the second active ingredient mixture respectively according to the average molecular weight;
[0019] A colistin sulfate standard is prepared, and the concentrations of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard are calculated based on the percentage contents of the active ingredients in the first active ingredient mixture and the second active ingredient mixture.
[0020] In an optional embodiment, the molecular formula of the first active ingredient mixture is:
[0021] C 53 H 100 N 16 O 13 2.5H2SO4;
[0022] The molecular formula of the second active ingredient mixture is:
[0023] C 52 H 98 N 16 O 13 2.5H2SO4;
[0024] The calculation method of the average molecular weight of the polymyxin E is:
[0025]
[0026] The average molecular weight of the polymyxin E is M=1159.12.
[0027] In an optional embodiment, the calculation method of the percentage of active ingredients in the first active ingredient mixture is:
[0028]
[0029] The percentage content of active ingredients in the first active ingredient mixture is W 1168 28.6%
[0030] The calculation method of the percentage of active ingredients in the second active ingredient mixture is:
[0031]
[0032] The percentage content of active ingredients in the second active ingredient mixture is W 1154 It is 47.5%.
[0033] In an optional embodiment, the concentration of the first active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0034] C 第一 =C 标准 ×W 1168 ;
[0035] The concentration of the second active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0036] C 第二 =C 标准 ×W 1154 ;
[0037] Among them, C 第一 represents the concentration of the first active ingredient mixture in the colistin sulfate standard; C 第二 represents the concentration of the second active ingredient mixture in the colistin sulfate standard; C 标准 represents the concentration of the colistin sulfate standard; W 1168 represents the percentage content of the active ingredient in the first active ingredient mixture; W 1154 Represents the percentage content of the active ingredient in the second active ingredient mixture.
[0038] In an optional embodiment, the preparation of a target sample to be tested corresponding to the whole blood sample and to which an internal standard is added comprises:
[0039] Centrifuge the whole blood sample to obtain the upper serum;
[0040] Adding the internal standard substance to the serum, and adding acetonitrile to perform protein precipitation treatment to obtain an intermediate;
[0041] The intermediate products are mixed and centrifuged, and the supernatant is taken as the target sample to be tested;
[0042] Preferably, the internal standard is acetaminophen.
[0043] In an optional embodiment, the liquid chromatography-mass spectrometry method is used to detect the colistin sulfate standard and the target sample, and the chromatographic conditions include at least one of the following conditions:
[0044] A. Mobile phase solvent: acetonitrile solution, or acetonitrile solution + 0.2% acetic acid solution;
[0045] B. Elution method: gradient elution for 6 minutes;
[0046] During gradient elution, calculated based on the acetonitrile ratio:
[0047] 0-1.0min: 5%; 1.0-3.0min: 25-45%; 3.0-4.0min: 45%; 4.0-6.0min: 5%;
[0048] C. Flow rate: 0.5 mL / min;
[0049] D. C 18 Chromatographic column.
[0050] In an optional embodiment, the calculation method of the blood concentration of polymyxin E in the target sample to be tested is:
[0051] C 多黏菌素E =C 第一测 +C 第二测 ;
[0052] Among them, C 多黏菌素E represents the blood concentration of polymyxin E in the target sample to be tested; C 第一测 represents the measured concentration of the first active ingredient mixture in the target sample; C 第二测 Represents the measured concentration of the second active ingredient mixture in the target sample.
[0053] In a second aspect, the present invention provides a detection product based on the method for determining the blood concentration of polymyxin E according to any one of the aforementioned embodiments, wherein the detection product comprises at least one of a detection kit and a detection device.
[0054] The method for determining the blood concentration of polymyxin E provided by the present invention is based on liquid chromatography-mass spectrometry, which avoids the main component-based method in conventional technology, and instead classifies polymyxin E by molecular weight, and deducts the sulfuric acid content therefrom to obtain the blood concentration of polymyxin E, thereby greatly improving the accuracy of polymyxin E detection, being simple to operate and having strong versatility, and being suitable for determining the content of polymyxin E when colistin sulfate or CMS is used clinically. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0056] Figure 1 This is a schematic diagram of the process in the embodiment of the method for determining the blood concentration of colistin E in this application;
[0057] Figure 2 The mass spectrum of blank plasma in Example 1 of the method for determining the blood concentration of colistin E in this application;
[0058] Figure 3 This is the mass spectrum of the colistin sulfate standard solution in Example 1 of the method for determining the blood concentration of colistin E in this application. DETAILED DESCRIPTION
[0059] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.
[0060] In an embodiment of the present application, a method for determining the blood concentration of polymyxin E is provided. The method is based on liquid chromatography-mass spectrometry, classifies polymyxin E by molecular weight, and deducts the sulfuric acid content therefrom to obtain the blood concentration of polymyxin E.
[0061] As mentioned above, Liquid Chromatography-Mass Spectrometry (LC-MS) is an analytical method that combines the separation technology of liquid chromatography (LC) with the detection technology of mass spectrometry (MS). This method is widely used in the fields of chemistry, biology, medicine, environmental science and food science for qualitative analysis, quantitative analysis and structural identification of target compounds in complex samples.
[0062] As mentioned above, Colistin E (also known as Colistin or Polymyxin E) is a polypeptide antibiotic, belonging to the polymyxin antibiotic family. This class of drugs was originally isolated from Bacillus polymyxa and has strong antibacterial activity, especially against Gram-negative bacteria, including some multi-drug resistant strains.
[0063] It should be noted that in the determination of the blood concentration of polymyxin E, the sulfuric acid content is deducted to ensure the accuracy and clinical relevance of the determination results. Since the antibacterial activity of polymyxin E mainly comes from its polypeptide structure rather than sulfate, it is crucial to exclude the mass of sulfate in the determination process to accurately reflect the concentration of the active ingredient of the drug in the body. This can avoid overestimation of drug concentration due to the increase in the overall mass of the sample due to sulfate, thereby improving the accuracy of therapeutic drug monitoring (TDM) and ensuring the scientificity and rationality of dose adjustment. In addition, standardized determination methods help to make the determination results of different laboratories or at different time points comparable, which is very important for clinical decision-making and research. Considering that polymyxin E has a narrow therapeutic window, accurately determining the concentration of the active ingredient is of great significance for avoiding adverse reactions, ensuring efficacy, and achieving individualized treatment. Therefore, the blood concentration data obtained after deducting the sulfuric acid content can better reflect the clinical effect of the drug and provide a reliable scientific basis for clinical treatment.
[0064] In the determination of the blood concentration of polymyxin E, if only the two main components E1 and / or E2 are considered for detection, other active isomers will be ignored. Although these isomers are present in smaller amounts, their contribution to the overall activity of the drug cannot be ignored. Traditional analytical methods may not be able to effectively distinguish and measure, and ignore these isomers, resulting in the measurement results being unable to accurately reflect the actual active ingredient concentration of the drug. The method of classifying polymyxin E by molecular weight for concentration determination uses liquid chromatography-mass spectrometry (LC-MS) to accurately distinguish and measure all components of polymyxin E based on molecular weight or mass-to-charge ratio, including those isomers with smaller amounts.
[0065] The advantage of this method is that it can provide more comprehensive analytical results, ensure the accuracy and reliability of the measurement results, and thus better reflect the clinical pharmacodynamic activity of the drug. In addition, by considering all active ingredients, this method can more realistically evaluate the therapeutic window and potential toxicity of the drug, provide a more accurate scientific basis for clinical therapeutic drug monitoring (TDM), and help optimize dose adjustments, improve therapeutic effects, and reduce the risk of adverse reactions. Therefore, the concentration determination of polymyxin E by molecular weight classification is a more scientific and comprehensive analytical strategy.
[0066] For further reference, Figure 1 , the method for determining the blood concentration of polymyxin E comprises:
[0067] Step S1, prepare a colistin sulfate standard, and calculate the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 by deducting the sulfuric acid content based on the molecular weight; and prepare a target sample to be tested corresponding to the whole blood sample to which an internal standard is added.
[0068] As mentioned above, colistin sulfate standards with known concentrations are prepared. These standards are used to establish a standard curve, which is the basis for quantitative analysis. The concentration of the active ingredient in the standard is ensured to be accurate by deducting the sulfuric acid content from the molecular weight. Thus, accurately prepared standards can be obtained, providing a benchmark for subsequent quantitative analysis.
[0069] In the above-mentioned method for determining the blood concentration of polymyxin E, 1168 and 1154 refer to the molecular weights of the two main active ingredients in polymyxin E. These molecular weights represent the weights of the molecular structures of different components in polymyxin E and are key parameters for distinguishing different compounds in mass spectrometry analysis.
[0070] (1) 1168: represents the polymyxin E component with a molecular weight of 1168, which refers to polymyxin E1 and its isomers. Polymyxin E1 is one of the main antibacterial components in polymyxin E and has important clinical application value.
[0071] (2) 1154: represents the polymyxin E component with a molecular weight of 1154, which refers to polymyxin E2 and its isomers. Polymyxin E2 is also a key antibacterial component in polymyxin E, and works together with E1 to fight against a variety of Gram-negative bacteria.
[0072] In liquid chromatography-mass spectrometry (LC-MS), the active ingredients in colistin can be accurately identified and quantified by detecting and comparing the molecular weights of these components in a sample. This method is able to provide more precise analytical results than traditional chromatographic techniques because it analyzes directly based on the mass of the molecule rather than relying on indirect parameters such as chromatographic retention time or UV absorption.
[0073] In the determination of blood concentration of polymyxin E, accurately distinguishing and quantifying these components with different molecular weights is crucial for evaluating the efficacy and safety of the drug, as they may have different pharmacological activities and toxicity characteristics. With this approach, the clinical application of polymyxin E can be more fully understood and controlled.
[0074] In this step, deducting the sulfuric acid content during the calculation process can avoid the interference of sulfate ions on the determination of active ingredient concentration and improve the accuracy of the analysis.
[0075] Step S2, based on liquid chromatography-mass spectrometry, the colistin sulfate standard and the target sample are detected to obtain detection data of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard, and the target sample;
[0076] Prepare the whole blood sample to be tested and add the internal standard for subsequent detection and quantitative analysis. The addition of the internal standard helps to correct the deviation in the sample preparation and analysis process and improve the accuracy and repeatability of the determination.
[0077] An appropriate amount of internal standard, such as acetaminophen, is added to the whole blood sample, followed by appropriate sample treatment, such as protein precipitation or extraction.
[0078] Step S3, constructing standard curves of the first active ingredient mixture and the second active ingredient mixture respectively according to the detection data;
[0079] As mentioned above, LC-MS technology is used to analyze the standard and the sample to be tested to obtain the detection data of each component. Obtaining detailed component information, including molecular weight, concentration, etc., is helpful for subsequent quantitative analysis. LC-MS technology has high sensitivity and high specificity, and can accurately distinguish and determine the active ingredients in complex biological samples.
[0080] The LC-MS system is used to perform chromatographic separation and mass spectrometry detection of the samples, and the obtained chromatograms and mass spectra are analyzed by software.
[0081] Step S4, calculating the measured concentrations of the first active ingredient mixture and the second active ingredient mixture in the target sample according to the standard curve; and calculating the blood concentration of polymyxin E in the target sample according to the measured concentrations of the first active ingredient mixture and the second active ingredient mixture.
[0082] Based on the test data of the standard, a standard curve of the first active ingredient mixture and the second active ingredient mixture is constructed. The standard curve is used to convert the response signal in the sample to be tested into the actual concentration, which is the key to quantitative analysis. The concentration of each component in the sample to be tested can be accurately calculated through the standard curve.
[0083] Use data processing software to construct a standard curve based on the concentration and response signal (such as peak area) of the standard using linear regression or other appropriate mathematical models.
[0084] The concentrations of the first active ingredient mixture and the second active ingredient mixture in the sample to be tested are calculated using the constructed standard curve, and the total blood concentration of polymyxin E is obtained accordingly. Obtaining accurate blood concentration of polymyxin E provides important reference data for clinical treatment. This method takes into account all major active ingredients and improves the comprehensiveness and accuracy of the test results.
[0085] According to the response signal of the sample to be tested, the concentration of each component is calculated by back-calculating the standard curve, and then the total concentration of polymyxin E is calculated.
[0086] Furthermore, in step S1, a colistin sulfate standard is prepared, and the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 are calculated by molecular weight after deducting the sulfuric acid content, respectively, including:
[0087] Step S11, calculating the average molecular weight of colistin based on the first active ingredient mixture with a molecular weight of 1168 and the second active ingredient mixture with a molecular weight of 1154;
[0088] The average molecular weight of polymyxin E was calculated based on the first active ingredient mixture with a molecular weight of 1168 and the second active ingredient mixture with a molecular weight of 1154. Thus, the average molecular weight of polymyxin E was obtained, providing basic data for subsequent concentration calculations.
[0089] Specifically, the average molecular weight can be obtained by chemical calculation by multiplying the molecular weight of each component by its mass percentage in the mixture and then adding them together.
[0090] Step S12, calculating the percentage of active ingredients in the first active ingredient mixture and the second active ingredient mixture respectively according to the average molecular weight;
[0091] As described above, the percentage of active ingredients of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard are calculated based on the average molecular weight. Obtaining the accurate percentage of each active ingredient in the standard is crucial for accurate preparation of the standard and subsequent quantitative analysis.
[0092] The percentage of each component can be calculated using formulas, usually involving mass balance and chemical analysis.
[0093] Step S13, preparing a colistin sulfate standard, and calculating the concentrations of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard according to the percentage contents of the active ingredients in the first active ingredient mixture and the second active ingredient mixture.
[0094] As described above, based on the calculated percentage of active ingredients, a colistin sulfate standard containing a first active ingredient mixture and a second active ingredient mixture of known concentrations is prepared.
[0095] As described above, the actual concentrations of the first active ingredient mixture and the second active ingredient mixture in the standard are calculated based on the percentage of active ingredients. Obtaining the accurate concentration of the standard for LC-MS analysis is crucial for constructing a standard curve and subsequent quantitative analysis.
[0096] Furthermore, the molecular formula of the first active ingredient mixture is:
[0097] C 53 H 100 N 16 O 13 2.5H2SO4;
[0098] Above, this is the molecular formula of Polymyxin E1 with a molecular weight of 1168 and related isomers with the same molecular weight. It shows that the compound in the mixture is composed of 53 carbon atoms, 100 hydrogen atoms, 16 nitrogen atoms, 13 oxygen atoms and 2.5 sulfuric acid molecules.
[0099] The molecular formula of the second active ingredient mixture is:
[0100] C 52 H 98 N 16 O 13 2.5H2SO4;
[0101] Above, this is the molecular formula of Polymyxin E2 with a molecular weight of 1154 and related isomers with the same molecular weight. It shows that the compound in the mixture is composed of 52 carbon atoms, 98 hydrogen atoms, 16 nitrogen atoms, 13 oxygen atoms and 2.5 sulfuric acid molecules.
[0102] In chemical and pharmaceutical analysis, both molecular formula and chemical structural formula are important tools for describing compounds. The chemical molecular formula is used here instead of the structural formula, mainly because the molecular formula is suitable for describing a series of compounds, especially when isomers or similar compounds are involved. It does not rely on specific stereochemical or configuration information, which may not be required in the preliminary description of the analytical method.
[0103] The calculation method of the average molecular weight of the polymyxin E is:
[0104]
[0105] The average molecular weight of the polymyxin E is M=1159.12.
[0106] The above calculation method is used to determine the weighted average molecular weight of colistin E, which takes into account the molecular weights of different components and their mass percentages in the mixture. In the mixture of colistin E, there are multiple components, each with different molecular weights and contents.
[0107] 1168, represents a first active ingredient mixture with a molecular weight of 1168 (such as Polymyxin E1 and its isomers).
[0108] 1154 represents a second active ingredient mixture with a molecular weight of 1154 (such as Polymyxin E2 and its isomers).
[0109] 1140 and 1166, representing other active ingredients with different molecular weights.
[0110] 30.46% and 4.239% are the mass percentages of the component with a molecular weight of 1168 in polymyxin E.
[0111] 53.8%, 0.843% and 2.915% are the mass percentages of the component with a molecular weight of 1154 in polymyxin E.
[0112] 1.076% and 1.111% are the mass percentages of components with molecular weights of 1140 and 1166 in polymyxin E.
[0113] Formula 1 is obtained by multiplying the molecular weight of each component by its corresponding mass percentage and then adding all these products to obtain the numerator. The denominator is the sum of the mass percentages of all components. This calculation method reflects the contribution of each component to the average molecular weight of the mixture.
[0114] This average molecular weight provides a representative value for describing the average molecular size of polymyxin E as a whole. This is very important for drug analysis, dosage determination, drug design and drug effect evaluation.
[0115] This average molecular weight can be used to identify and quantify individual components of colistin in liquid chromatography-mass spectrometry (LC-MS) analysis, as well as to assess drug concentrations in vivo in therapeutic drug monitoring (TDM).
[0116] This weighted average molecular weight calculation method can more accurately reflect the properties of complex mixtures such as polymyxin E. This method takes into account the contributions of all important components in the mixture and provides a comprehensive parameter that helps to better understand and apply this substance.
[0117] Furthermore, the calculation method of the percentage of active ingredients in the first active ingredient mixture is:
[0118]
[0119] The percentage content of active ingredients in the first active ingredient mixture is W 1168 28.6%
[0120] The calculation method of the percentage of active ingredients in the second active ingredient mixture is:
[0121]
[0122] The percentage content of active ingredients in the second active ingredient mixture is W 1154 It is 47.5%.
[0123] The above calculation method is used to determine the percentage of active ingredients in the first active ingredient mixture and the second active ingredient mixture in polymyxin E, that is, the percentage of active ingredients (polypeptide part) in polymyxin E after removing sulfate (H2SO4). This calculation is very important for accurately evaluating the actual active ingredients of drugs, especially in drug analysis and therapeutic drug monitoring (TDM).
[0124] In Formula 2, the numerator is: M×(30.46%+4.239%), where M is the average molecular weight of polymyxin E, 1159.12, and 30.46%+4.239% is the mass percentage of the component with a molecular weight of 1168 (such as Polymyxin E1 and its isomers) in polymyxin E. The denominator is: M+2.5×98, where 2.5×98 represents the total molecular weight of sulfate groups, because each polymyxin E molecule is combined with 2.5 sulfuric acid molecules (the molecular weight of each sulfuric acid molecule is about 98).
[0125] In Formula 3, the numerator is: M×(53.8%+0.843%+2.915%), where M is the average molecular weight of polymyxin E, 1159.12, and 53.8%+0.843%+2.915% is the mass percentage of the component with a molecular weight of 1154 (such as Polymyxin E2 and its isomers) in polymyxin E. The denominator is the same as Formula 2, taking into account the molecular weight of the sulfate group.
[0126] W 1168 and W 1154 The calculated results are 28.6% and 47.5%, respectively, which means that after considering the contribution of sulfate, the active ingredient (polypeptide part) in the first and second active ingredient mixtures accounts for 28.6% and 47.5% of the total mass.
[0127] By deducting the molecular weight of the sulfate group, the proportion of the actual active ingredient in colistin can be more accurately assessed, which is crucial for determining drug dosage and evaluating efficacy. This calculation method provides a standardized way to evaluate the quality of colistin from different batches or sources, helping to ensure the consistency and reliability of the drug. The accurate percentage of active ingredients helps clinicians better understand the drug's mechanism of action and dosage effect, thereby optimizing treatment plans.
[0128] In short, this calculation method can more accurately evaluate the actual content of active ingredients in polymyxin E, which is of great significance for drug development, production, quality control and clinical application. This method takes into account the influence of inactive parts (such as sulfate) in drug molecules and provides an evaluation method that is closer to the actual proportion of active ingredients.
[0129] Furthermore, the concentration of the first active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0130] C 第一 =C 标准 ×W 1168 ;(Formula 4)
[0131] The concentration of the second active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0132] C 第二 =C 标准 ×W 1154 ;(Formula 5)
[0133] Among them, C 第一 represents the concentration of the first active ingredient mixture in the colistin sulfate standard; C 第二 represents the concentration of the second active ingredient mixture in the colistin sulfate standard; C 标准 represents the concentration of the colistin sulfate standard; W 1168 represents the percentage content of the active ingredient in the first active ingredient mixture; W 1154 Represents the percentage content of the active ingredient in the second active ingredient mixture.
[0134] Furthermore, in step S1, preparing a target sample to be tested corresponding to the whole blood sample and having an internal standard added thereto comprises:
[0135] Step S14, centrifuging the whole blood sample to obtain the upper layer of serum;
[0136] Step S15, adding the internal standard substance to the serum, and adding acetonitrile to perform protein precipitation treatment to obtain an intermediate;
[0137] Step S16, mixing the intermediate products and centrifuging them, and taking the supernatant as the target sample to be tested;
[0138] As mentioned above, centrifugation can be performed at high speed using a centrifuge. Then, the upper plasma is accurately sampled by a pipette, which is serum. Then, it is transferred to a centrifuge tube, an internal standard is added, and protein precipitation is performed with acetonitrile. A vortex oscillator is used for mixing, and then centrifugation is performed in a centrifuge to obtain the target sample to be tested.
[0139] Furthermore, the internal standard is acetaminophen.
[0140] Furthermore, the liquid chromatography-mass spectrometry method is used to detect the colistin sulfate standard and the target sample, and the chromatographic conditions include at least one of the following conditions:
[0141] A. Mobile phase solvent: acetonitrile solution, or acetonitrile solution + 0.2% acetic acid solution;
[0142] B. Elution method: gradient elution for 6 minutes;
[0143] During gradient elution, calculated based on the acetonitrile ratio:
[0144] 0-1.0min: 5%; 1.0-3.0min: 25-45%; 3.0-4.0min: 45%; 4.0-6.0min: 5%;
[0145] C. Flow rate: 0.5 mL / min;
[0146] D. C 18 Chromatographic column.
[0147] Furthermore, the calculation method of the blood concentration of polymyxin E in the target sample to be tested is:
[0148] C 多黏菌素E =C 第一 +C 第二 ;(Formula 6)
[0149] Wherein, C polymyxin E represents the blood concentration of polymyxin E in the target sample to be tested; C first represents the measured concentration of the first active ingredient mixture in the target sample to be tested; and C second represents the measured concentration of the second active ingredient mixture in the target sample to be tested.
[0150] In addition, an embodiment of the present application also provides a detection product based on the method for determining the blood concentration of polymyxin E described in any of the aforementioned embodiments, and the detection product includes at least one of a detection kit and a detection device.
[0151] The detection kit may include but is not limited to:
[0152] Colistin E standard substances, internal standards, protein precipitation solvents, preparation solvents and mobile phase solvents.
[0153] The above-mentioned kit is based on the aforementioned method for determining the blood concentration of polymyxin E. The kit should contain the following reagents and supplies to implement the various steps in the method:
[0154] (1) Polymyxin E standard substance:
[0155] The material used to prepare the colistin sulfate standard should contain polymyxin E of known purity and concentration.
[0156] (2) Internal standard:
[0157] Used to correct the deviation in the determination process, preferably, the internal standard is acetaminophen or other suitable compounds.
[0158] (3) Protein precipitation solvent:
[0159] Serum samples are treated to precipitate proteins and release colistin, usually with acetonitrile or other organic solvents.
[0160] (4) Preparation of solvent:
[0161] Used to dilute or dissolve reference materials and internal standards, which may include 50% methanol in water or other suitable solvents.
[0162] (5) Mobile phase solvent:
[0163] For liquid chromatography analysis, including acetonitrile solution or acetonitrile solution plus 0.2% acetic acid solution.
[0164] The detection equipment may include but is not limited to:
[0165] (1) Chromatographic column:
[0166] A C18 column was used for chromatography to achieve efficient separation of colistin E components.
[0167] (2) Sample processing equipment:
[0168] For the steps of mixing, settling and taking supernatant of samples, for example, it may include but is not limited to a vortex shaker, a centrifuge, a pipette, consumables for filtering and sampling, and the like.
[0169] (3) Mass spectrometer: used to detect and analyze the polymyxin E components after chromatographic separation.
[0170] The present invention is further described below by means of specific examples, but it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0171] 1. Experimental conditions used in the examples:
[0172] (1) Instruments: LC-MS system. QTRAP3200 (AB, USA); analytical balance: XP105DR (Mettler Toledo, Switzerland); ultrapure water system: Milli-Q Integral (Merck, Germany).
[0173] (2) Drugs and reagents: Colistin sulfate standard (polymyxin E sulfate) (batch number: V-919300-NU2, total active ingredient: 95.40%, CFW labs, Table 1); acetaminophen (internal standard) (batch number: 100018-201508, content: 99.4%, China Food and Drug Inspection Institutes); chromatographic acetonitrile (Fisher Scientific); healthy human blank plasma was obtained from the physical examination center of a tertiary medical institution in Beijing.
[0174] Table 1. Statistics of colistin sulfate components
[0175]
[0176] (3) Chromatographic conditions: Agilent Poroshell 120SB C18 column (specifications: 4.6 mm × 50 mm, 2.7 μm) was used, the mobile phase was acetonitrile / 0.2% acetic acid solution, gradient elution, room temperature, flow rate was 0.5 mL / min, injection volume was 5 μL, and analysis time was 6.0 min. The proportion of acetonitrile was: 0-1.0 min: 5%; 1.0-3.0 min: 25-45%; 3.0-4.0 min: 45%; 4.0-6.0 min: 5%.
[0177] (4) Mass spectrometry conditions:
[0178] Electrospray ion source, multiple reaction monitoring (MRM), positive ion mode, curtain gas: 40 psi, ion source voltage: 5000 V, ion source temperature: 550° C. The mass spectrometry parameters of the compounds are shown in Table 2.
[0179] Table 2. Mass spectrometry parameters
[0180]
[0181] 2. Preparation of the standard solution used in the examples:
[0182] The molecular formula of the first active ingredient mixture is:
[0183] C 53 H 100 N 16 O 13 2.5H2SO4;
[0184] The molecular formula of the second active ingredient mixture is:
[0185] C 52 H 98 N 16 O 13 2.5H2SO4;
[0186] The calculation method of the average molecular weight of the polymyxin E is:
[0187]
[0188] The average molecular weight of the polymyxin E is M=1159.12.
[0189] The calculation method of the percentage of active ingredients in the first active ingredient mixture is:
[0190]
[0191] The percentage content of active ingredients in the first active ingredient mixture is W 1168 28.6%
[0192] The calculation method of the percentage of active ingredients in the second active ingredient mixture is:
[0193]
[0194] The percentage content of active ingredients in the second active ingredient mixture is W 1154 It is 47.5%.
[0195] The concentration of the first active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0196] C 第一 =C 标准 ×W 1168 ;
[0197] The concentration of the second active ingredient mixture in the colistin sulfate standard is calculated as follows:
[0198] C 第二 =C 标准 ×W 1154 ;
[0199] Among them, C 第一represents the concentration of the first active ingredient mixture in the colistin sulfate standard; C 第二 represents the concentration of the second active ingredient mixture in the colistin sulfate standard; C 标准 represents the concentration of the colistin sulfate standard; W 1168 represents the percentage content of the active ingredient in the first active ingredient mixture; W 1154 Represents the percentage content of the active ingredient in the second active ingredient mixture.
[0200] Based on the above, accurately weigh 1.50 mg of colistin sulfate standard into a 10 mL volumetric flask, dissolve it in 50% methanol solution and dilute to the mark. Calculate the following:
[0201] The concentration of the active ingredient with a molecular weight of 1168 (C 第一 ) was 42.90 μg / mL.
[0202] The active ingredient (C 第二 ) was 71.25 μg / mL.
[0203] Protect from light and place in a -20℃ refrigerator until ready for use.
[0204] 3. Preparation of internal standard:
[0205] Accurately weigh 1.61 mg of acetaminophen standard and place it in a 10 mL volumetric flask. Dissolve it in 50% methanol solution and make up to the mark to obtain 161.00 μg / mL of acetaminophen standard solution. Place it in the refrigerator for later use as an internal standard.
[0206] 4. Preparation of target samples:
[0207] First, the whole blood sample was placed in a centrifuge for high-speed centrifugation. 100 μl of the upper plasma was accurately measured with a pipette and placed in a 1.5 mL centrifuge tube. 10 μl of the internal standard in step 3 was added. Protein precipitation was performed with 200 μl of acetonitrile. The mixture was vortexed for 1 min and centrifuged for 3 min (14000 r / min). -1 , 4°C), and 5 μl of the supernatant was injected for analysis.
[0208] 5. Detection and analysis calculation:
[0209] Based on liquid chromatography-mass spectrometry, the colistin sulfate standard prepared in the above step and the target sample are tested to obtain the detection data of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard, and the target sample;
[0210] constructing standard curves of the first active ingredient mixture and the second active ingredient mixture respectively according to the detection data;
[0211] According to the standard curve, the measured concentrations of the first active ingredient mixture and the second active ingredient mixture in the target sample to be tested are calculated; and the blood concentration of polymyxin E in the target sample to be tested is calculated according to the measured concentrations of the first active ingredient mixture and the second active ingredient mixture.
[0212] The calculation method of the blood concentration of polymyxin E in the target sample to be tested is:
[0213] C 多黏菌素E =C 第一测 +C 第二测 ;
[0214] Among them, C 多黏菌素E represents the blood concentration of polymyxin E in the target sample to be tested; C 第一测 represents the measured concentration of the first active ingredient mixture in the target sample; C 第二测 Represents the measured concentration of the second active ingredient mixture in the target sample.
[0215] Example 1: Investigation of method specificity.
[0216] Experimental methods:
[0217] In this example, blank plasma (whole blood samples) and blank plasma containing colistin sulfate standard and internal standard were obtained from different healthy subjects.
[0218] Based on the experimental conditions in the aforementioned method 1, the preparation of the standard solution in method 2, the preparation of the internal standard in method 3, and the preparation of the target sample in method 4, after sample processing and setting, the aforementioned method 5 was used for analysis to obtain a mass spectrum.
[0219] Experimental results:
[0220] Depend on Figure 2 and Figure 3 It can be seen that T 第一活性成分混合物 3.17min, T 第二活性成分混合物 It is 3.16min. Figure 3 A is the original mass spectrum; B is the mass spectrum peak of the separated second active ingredient mixture (3.16min); C is the mass spectrum peak of the separated first active ingredient mixture (3.17min); D is the mass spectrum peak of the internal standard (3.25min). The mass spectrum of the blank plasma of healthy people has no peak at the relevant time point, indicating that the endogenous substances have no interference with the determination.
[0221] Example 2: Investigation of linear relationship.
[0222] Experimental methods:
[0223] (1) First, dilute the colistin sulfate stock solution with 50% methanol solution, wherein:
[0224] First active ingredient mixture: 42.90 μg / mL, 21.45 μg / mL, 14.30 μg / mL, 7.15 μg / mL, 2.86 μg / mL, 1.43 μg / mL, 0.286 μg / mL, 0.143 μg / mL;
[0225] Second active ingredient mixture: 71.25 μg / mL, 35.625 μg / mL, 23.75 μg / mL, 11.875 μg / mL, 4.75 μg / mL, 2.375 μg / mL, 0.475 μg / mL, 0.2375 μg / mL.
[0226] (2) Use a pipette to measure 90 μl of each of the 8 blank plasmas in parallel, and add 10 μl of the above series of concentration standard solutions to obtain:
[0227] First active ingredient mixture: 4.29 μg / mL, 2.145 μg / mL, 1.43 μg / mL, 0.715 μg / mL, 0.286 μg / mL, 0.143 μg / mL, 0.0286 μg / mL, 0.0143 μg / mL;
[0228] Second active ingredient mixture: 7.125 μg / mL, 3.563 μg / mL, 2.375 μg / mL, 1.188 μg / mL, 0.475 μg / mL, 0.238 μg / mL, 0.0475 μg / mL, 0.0238 μg / mL.
[0229] (3) Based on the experimental conditions in the aforementioned method 1, the preparation of the standard solution in method 2, the preparation of the internal standard in method 3, and the preparation of the target sample in method 4, after sample processing and setting, the aforementioned method 5 is used for analysis.
[0230] The ordinate (Y) is the ratio of the sample peak area to the internal standard peak area, and the abscissa (X) is the concentration. The respective regression curves are drawn (Table 3).
[0231] Experimental results:
[0232] Table 3. Linear relationship of colistin sulfate
[0233] Analytes Linear Relationship Weight r-value Linear range (μg / mL) E1 Y=1.61X+0.0456 1 / x 0.9997 0.0143~4.29 E2 Y=0.96X+0.0386 1 / x 0.9990 0.0238~7.125
[0234] It can be seen from the table that the first active ingredient mixture and the second active ingredient mixture have a good linear relationship within their respective linear ranges.
[0235] Example 3: Investigation of precision and accuracy.
[0236] Experimental methods:
[0237] In this embodiment, 90 μl of each of the three blank plasmas were measured in parallel with a pipette, and 10 μl of each of the three concentration standard solutions were added to the corresponding portions, including:
[0238] First active ingredient mixture: 2.145 μg / mL, 0.715 μg / mL, 0.0286 μg / mL;
[0239] Second active ingredient mixture: 3.563 μg / mL, 1.188 μg / mL, 0.0475 μg / mL;
[0240] The above three concentrations were used as high, medium and low quality control samples respectively.
[0241] Based on the experimental conditions in the aforementioned method 1, the preparation of the standard solution in method 2, the preparation of the internal standard in method 3, and the preparation of the target sample in method 4, after sample processing and setting, the aforementioned method 5 is used for analysis.
[0242] The measured value is expressed as ˉX±s. Five samples of each concentration were prepared in parallel, and five batches of samples were prepared within 5 days using the same method.
[0243] Experimental results:
[0244] Table 4. Precision and accuracy of colistin sulfate (n=5)
[0245]
[0246] The results are shown in Table 4. It can be seen from the table that the high, medium and low quality control samples of the first active ingredient mixture and the second active ingredient mixture all have good precision and accuracy, and the RSD and relative deviation RE are both less than 10%.
[0247] Example 4: Investigation of extraction recovery and matrix effect.
[0248] Experimental methods:
[0249] According to the three groups of quality control, high, medium and low, each group used a pipette to measure 90 μl of blank plasma from different healthy people in parallel, and added 10 μl of the above three concentrations of standard solution, including:
[0250] First active ingredient mixture: 2.145 μg / mL, 0.715 μg / mL, 0.0286 μg / mL;
[0251] Second active ingredient mixture: 3.563 μg / mL, 1.188 μg / mL, 0.0475 μg / mL;
[0252] The above three concentrations were set as high, medium and low quality control samples respectively.
[0253] Based on the experimental conditions in the aforementioned method 1, the preparation of the standard solution in method 2, the preparation of the internal standard in method 3, and the preparation of the target sample in method 4, after sample processing and setting, the aforementioned method 5 was used for analysis to obtain the peak area A0.
[0254] In addition, first measure 1 mL of blank plasma from different healthy people, first use 2 mL of acetonitrile to precipitate protein, and then centrifuge to obtain supernatant. Replace blank plasma with the supernatant, repeat the above operation, and obtain the peak area A1 of each supernatant sample. Next, replace the supernatant with pure water, repeat the above operation, and obtain the peak area A2 of each aqueous solution.
[0255] A0 / A1*100% is the extraction recovery rate;
[0256] A1 / A2*100% is the matrix effect.
[0257] Experimental results:
[0258] Table 5. Colistin sulfate extraction recovery and matrix effect (n=6)
[0259]
[0260] The results are shown in Table 5. The extraction recovery rates of the first active ingredient mixture were 74.16% to 84.55%, and the extraction recovery rates of the second active ingredient mixture were 72.60% to 87.37%. The matrix effect had little influence on the first active ingredient mixture and the second active ingredient mixture.
[0261] Example 5: Stability study.
[0262] Experimental methods:
[0263] Use a pipette to measure 90 μl of each of the three blank plasmas in parallel, and add 10 μl of each of the three concentrations of standard solution mentioned above, including:
[0264] First active ingredient mixture: 2.145 μg / mL, 0.715 μg / mL, 0.0286 μg / mL;
[0265] Second active ingredient mixture: 3.563 μg / mL, 1.188 μg / mL, 0.0475 μg / mL;
[0266] The above three concentrations were used as high, medium and low quality control samples, respectively. Three samples of each concentration were prepared in parallel to examine the stability of the first active ingredient mixture and the second active ingredient mixture after being placed at room temperature for 24 hours and frozen and thawed three times at -80°C.
[0267] Based on the experimental conditions in the aforementioned method 1, the preparation of the standard solution in method 2, the preparation of the internal standard in method 3, and the preparation of the target sample in method 4, after sample processing and setting, the aforementioned method 5 is used for analysis.
[0268] Experimental results:
[0269] Table 6 Colistin sulfate stability (n=3)
[0270]
[0271] The results are shown in Table 6. The change rates of the quality control samples of high, medium and low concentrations of the first active ingredient mixture and the second active ingredient mixture were all less than 10% under the two treatment modes, indicating that the stability of the first active ingredient mixture and the second active ingredient mixture was good.
[0272] Analysis and discussion of experimental results in the embodiments:
[0273] With the increasing proportion of hospital infections caused by CRO and the lack of effective therapeutic drugs, polymyxins have received more and more attention in clinical practice. At present, there are three types of injectable polymyxins on the market at home and abroad, including polymyxin B sulfate for injection, polymyxin E sodium methanesulfonate for injection (colistin sodium methanesulfonate for injection, CMS) and colistin sulfate for injection (polymyxin E sulfate for injection, trade name: Fengweiling), the latter of which is currently only used clinically in my country. Since polymyxins have a narrow therapeutic window and present a greater risk of nephrotoxicity, TDM is recommended when using polymyxins. At present, TDM methods for polymyxins are mostly concentrated on high-performance liquid chromatography and liquid chromatography-mass spectrometry.
[0274] For high performance liquid chromatography, the analyte needs to have ultraviolet absorption and be able to achieve baseline separation in order to accurately perform quantitative analysis. On the one hand, polymyxin E has low ultraviolet absorption, with a maximum absorption wavelength of 210 nm, which is terminal absorption and has no native fluorescence, so the analysis requires high sensitivity of the mobile phase and detector. Li J et al. and Gmur DJ et al. used fluorenylmethoxycarbonyl chloride (Fmoc-Cl) and dansyl chloride to derivatize plasma extracts, respectively. The maximum absorption wavelength of the analyte after derivatization was red-shifted, but this made the sample processing process cumbersome. On the other hand, since polymyxin E is a biological fermentation product with many components (see Table 1), in order to accurately quantify the two main components A and B, it is necessary to achieve baseline separation between the components. In order to achieve this goal, the reported methods for determining the content of polymyxin E using liquid chromatography mostly have an analysis time of 20 to 30 minutes, which is a long time. More importantly, the clinical antimicrobial activity of polymyxin E should be the result of the combined action of other active ingredients in addition to impurities. Based on this conclusion, even if the baseline separation accurately quantifies the two main components A and B, their concentration results cannot truly reflect the clinical antimicrobial activity of polymyxin E.
[0275] The analytical principle of liquid chromatography-mass spectrometry is based on the molecular weight or mass-to-charge ratio of the analyte, and the analyte can be accurately quantified without baseline separation. For polymyxin E, the reported LC-MS analysis time is mostly about 5 minutes, which is convenient and fast. But there are also problems. LC-MS cannot distinguish isomers, such as A and E with a molecular weight of 1168, and B, C and D with a molecular weight of 1154. Therefore, in actual measurement, the ion pairs 585.440→101.100 and 578.418→101.000 are actually the sum of the concentrations of A, B, C, D, and E. However, when calculating the standard curve, A and B are mainly used, and C, D, and E with less content are ignored (the three together account for about 8% and should not be ignored). This causes the measured concentration to be lower than the true value, which is a mistake rather than an error. For drugs with a narrow therapeutic window such as polymyxin E, the above situation should be avoided. Of course, the composition and content of polymyxin E varieties from different manufacturers and different batches may be different, but the above principles are the same.
[0276] In addition, the content of sulfuric acid in colistin sulfate is 17.45% (2.5*98 / (1159.12+2.5*98)), which accounts for a large proportion and cannot be ignored, but the publicly reported literature does not give a clear explanation for this situation. Considering the versatility of the LC-MS method established, that is, if CMS is used clinically, it is hydrolyzed to the main body of polymyxin E to exert its pharmacological activity, and the process does not involve sulfuric acid. If the sulfuric acid component is not deducted during the calculation of the standard curve, the measured concentration will be too high, which is obviously wrong. Therefore, the author believes that the sulfuric acid component should be deducted during the calculation of the standard curve to make the established method more universal and accurate.
[0277] Based on the above, in this application, a liquid chromatography-mass spectrometry method for the determination of polymyxin E content is established. In the process of calculating the standard curve, the classification is based on the molecular weight instead of the two main components A and B, and the content of sulfuric acid is deducted. Since the molecular weight of component G has not been found yet (the content is 0.953%), it can be ignored in the calculation process of the average molecular weight. In addition, although components F, G and H also participate in the antibacterial effect, they have different molecular weights and low contents. These components cannot be quantitatively measured by ion pairs 585.440→101.100 and 578.418→101.000. The concentration determined by the method established in this application has matched the clinical antibacterial effect results as much as possible.
[0278] The method established in the present application is simple to operate and has strong versatility, and is suitable for the determination of the content of polymyxin E when colistin sulfate or CMS is used clinically.
[0279] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for determining the blood concentration of polymyxin E, It is characterized in that The method for determining the blood concentration of polymyxin E is based on liquid chromatography-mass spectrometry, which classifies polymyxin E by molecular weight and deducts the sulfuric acid content therein to obtain the blood concentration of polymyxin E.
2. The method for determining the blood concentration of polymyxin E according to claim 1, It is characterized in that The method for determining the blood concentration of polymyxin E comprises: Prepare a colistin sulfate standard, and calculate the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 by deducting the sulfuric acid content from the molecular weight; and prepare a target sample to be tested corresponding to the whole blood sample to which an internal standard is added; Based on liquid chromatography-mass spectrometry, the colistin sulfate standard and the target sample are tested to obtain the detection data of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard, and the target sample; constructing standard curves of the first active ingredient mixture and the second active ingredient mixture respectively according to the detection data; According to the standard curve, the measured concentrations of the first active ingredient mixture and the second active ingredient mixture in the target sample to be tested are calculated; and the blood concentration of polymyxin E in the target sample to be tested is calculated according to the measured concentrations of the first active ingredient mixture and the second active ingredient mixture.
3. The method for determining the blood concentration of polymyxin E according to claim 2, It is characterized in that The method of preparing a colistin sulfate standard and calculating the concentration of the first active ingredient mixture with a molecular weight of 1168 and the concentration of the second active ingredient mixture with a molecular weight of 1154 respectively based on the molecular weight and the sulfuric acid content, comprises: The average molecular weight of polymyxin E was calculated based on the first active ingredient mixture with a molecular weight of 1168 and the second active ingredient mixture with a molecular weight of 1154; Calculating the percentage of active ingredients in the first active ingredient mixture and the second active ingredient mixture respectively according to the average molecular weight; A colistin sulfate standard is prepared, and the concentrations of the first active ingredient mixture and the second active ingredient mixture in the colistin sulfate standard are calculated based on the percentage contents of the active ingredients in the first active ingredient mixture and the second active ingredient mixture.
4. The method for determining the blood concentration of polymyxin E according to claim 3, It is characterized in that The molecular formula of the first active ingredient mixture is: C 53 H 100 N 16 Oh 13 ·2.5H 2 SO 4 ; The molecular formula of the second active ingredient mixture is: C 52 H 98 N 16 Oh 13 ·2.5H 2 SO 4 ; The calculation method of the average molecular weight of the polymyxin E is: The average molecular weight of the polymyxin E is M=1159.
12.
5. The method for determining the blood concentration of polymyxin E according to claim 4, It is characterized in that The calculation method of the percentage of active ingredients in the first active ingredient mixture is: The percentage content of active ingredients in the first active ingredient mixture is W 1168 28.6% The calculation method of the percentage of active ingredients in the second active ingredient mixture is: The percentage content of active ingredients in the second active ingredient mixture is W 1154 It is 47.5%.
6. The method for determining the blood concentration of polymyxin E according to claim 4, It is characterized in that The concentration of the first active ingredient mixture in the colistin sulfate standard is calculated as follows: C 第一 =C 标准 ×W 1168 ; The concentration of the second active ingredient mixture in the colistin sulfate standard is calculated as follows: C 第二 =C 标准 ×W 1154 ; Among them, C 第一 represents the concentration of the first active ingredient mixture in the colistin sulfate standard; C 第二 represents the concentration of the second active ingredient mixture in the colistin sulfate standard; C 标准 represents the concentration of the colistin sulfate standard; W 1168 represents the percentage content of the active ingredient in the first active ingredient mixture; W 1154 Represents the percentage content of the active ingredient in the second active ingredient mixture.
7. The method for determining the blood concentration of polymyxin E according to claim 2, It is characterized in that The target sample to be tested, in which an internal standard is added, corresponding to the prepared whole blood sample, comprises: Centrifuge the whole blood sample to obtain the upper serum; Adding the internal standard substance to the serum, and adding acetonitrile to perform protein precipitation treatment to obtain an intermediate; The intermediate products are mixed and centrifuged, and the supernatant is taken as the target sample to be tested; Preferably, the internal standard is acetaminophen.
8. The method for determining the blood concentration of polymyxin E according to claim 2, It is characterized in that The liquid chromatography-mass spectrometry method is used to detect the colistin sulfate standard and the target sample, and the chromatographic conditions include at least one of the following conditions: A. Mobile phase solvent: acetonitrile solution, or acetonitrile solution + 0.2% acetic acid solution; B. Elution method: gradient elution for 6 minutes; During gradient elution, calculated based on the acetonitrile ratio: 0-1.0min: 5%; 1.0-3.0min: 25-45%; 3.0-4.0min: 45%; 4.0-6.0min: 5%; C. Flow rate: 0.5 mL / min; D. C 18 Chromatographic column.
9. The method for determining the blood concentration of polymyxin E according to claim 2, It is characterized in that The calculation method of the blood concentration of polymyxin E in the target sample to be tested is: C 多黏菌素E =C 第一测 +C 第二测 ; Among them, C 多黏菌素E represents the blood concentration of polymyxin E in the target sample to be tested; C 第一测 represents the measured concentration of the first active ingredient mixture in the target sample; C 第二测 Represents the measured concentration of the second active ingredient mixture in the target sample.
10. A detection product based on the method for determining the blood concentration of polymyxin E according to any one of claims 1 to 9, It is characterized in that The detection product includes at least one of a detection kit and a detection device.
Citation Information
Cited By
Analysis method for detecting colistin in bacteria
CN120214133A
